SNU-475细胞
器官来源： 肝
ATCC Number： CRL-2236™
运输方式： 冻存运输
相关**： 肝癌
生长状态： 贴壁生长
年限： grade II-IV/V
数量： 大量
是否是肿瘤细胞： 1
物种来源： 人
细胞形态： 上皮样
Designations: SNU-475
Depositors: J Park
SNU-475细胞Biosafety Level: 2 [CELLS CONTAIN HEPATITIS B VIRUS ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent, monolayer of diffusely spreading cells
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: liver
Tumor Stage: grade II-IV/V
Disease: hepatocellular carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. SNU-475细胞Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995).
Antigen Expression: Blood Type AB; Rh +
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,11
D16S539: 12
D5S818: 10,13
D7S820: 7,12
THO1: 7,9
TPOX: 8,9
vWA: 14
Cytogenetic Analysis: aneuploid; modal number = 61
Age: 43 years
Gender: male
Ethnicity: Asian
SNU-475细胞Comments: SNU-475 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient prior to cytotoxic therapy.
Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat inactivated fetal bovine serum.
After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum.
Grossly, the original tumor was massive growth type.
Histologically, it was predominantly compact and minor trabecular type.
The cultured cells are multinucleated.
Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Doubling Time: 66 hrs
Related Products: SNU-475细胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
References: 22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080
